Condition: Alzheimer Disease · Agitation,Psychomotor · Care Giving Burden · Sponsor: IGC Pharma, LLC
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
This description comes directly from the study's public registry record.
Evelyn Gutiérrez · +13013394270 · calma@igcpharma.com
Margarita Venegas · mvenegas@igcpharma.com
Always discuss trial participation with your own doctor first.
| ClinCloud, LLC | Maitland, Florida, United States | Active Not Recruiting |
| ClinCloud, LLC | Melbourne, Florida, United States | Recruiting |
| Central Miami Medical Institute | Miami, Florida, United States | Recruiting |
| Visionary Investigators Network | Miami, Florida, United States | Recruiting |
| Miami Jewish Health | Miami, Florida, United States | Recruiting |
| Neurostudies Inc. | Port Charlotte, Florida, United States | Recruiting |
| BayCare Health System Inc. | St. Petersburg, Florida, United States | Recruiting |
| University of South Florida Department of Psychiatry and Behavioral Neurosciences | Tampa, Florida, United States | Recruiting |
| Tandem Clinical Research GI, LLC | Metairie, Louisiana, United States | Recruiting |
| MedStar Franklin Square Medical Center Neurology | Baltimore, Maryland, United States | Recruiting |
| Medstar Southern Maryland Hospital Center | Clinton, Maryland, United States | Recruiting |
| Medstar Montgomery Medical Center | Olney, Maryland, United States | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05543681